Issues related to pharmaceutical industry, generally; Issues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP)
2025 · 2nd Quarter (Apr 1 - June 30)
IPSEN BIOPHARMACEUTICALS, INC.
Filed by RICCHETTI INCORPORATED.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Termination
- Posted
- Jul 21, 2025
- Income
- $20,000.00
- Expenses
- Not reported
- Registrant
- RICCHETTI INCORPORATED
- Filing UUID
- 908df4f8-ac12-427f-ad22-37f91f24b553
- Termination date
- Jun 30, 2025
Literal source text
Lobbying issues and bill citations
Issues related to coverage of diagnostic testing for cancer; H.R.842/S.339, Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.